<DOC>
	<DOCNO>NCT01260974</DOCNO>
	<brief_summary>The aim study determine viable use caspofungin post-OLTx patient , demonstrate particular effectiveness , understood ability reduce incidence invasive fungal infection , assess ability reduce risk incidence side effect ( toxicity ) may arise transplant patient treat drug , especially individual recognize high risk ( e.g . renal failure ) .</brief_summary>
	<brief_title>Caspofungin Prophylaxis High Risk Liver Transplantation Recipients</brief_title>
	<detailed_description>The prophylactic use anti-fungal drug crucial order decrease incidence invasive fungal infection transplantation patient . Invasive fungal infection ( IFI ) -- -organ-related systemic infection -- - fact one important cause morbidity mortality patient undergo solid organ transplantation ( respectively , 70 % 100 % ) . The rationale propose study evaluate new protocol prevention IFIs use newly introduce anti-fungal , caspofungin ( commercial name : Cancidas ) , use primary prophylaxis fungal infection post-OLTx compare drug already use ( eg . amphotericin B , fluconazole ) , 21 day liver transplantation . The aim study determine viable use caspofungin post-OLTx patient , demonstrate particular effectiveness , understood ability reduce incidence invasive fungal infection , assess ability reduce risk incidence side effect ( toxicity ) may arise transplant patient treat drug , especially individual recognize high risk ( e.g . renal failure ) . The possibility reduce risk fungal infection liver transplant patient ( usually 7 42 % ) therefore important clinical goal .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Fungemia</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>patient shortlist liver transplantation negative pregnancy test fertile female patient 7 day prior enrollment patient adequately communicate study responsibles , understand answer protocol requirement At least one follow criterion : MELD score â‰¥25 liver transplantation acute liver failure liver retransplantation fever without bacterial viral infection biliodigestive relaparatomy LTx post LTx pancreatitis post LTx dialysis renal insufficiency Patients enrol clinical trial receive experimental drug 4 week prior enrollment Patients know fungal infection ( base EORTC/MSG criterion ) Patients history hypersensitivity drug , counterindications Patients diagnose Severe Hepatic insufficiency ( CTP &gt; 9 ) Physical hematochemical alteration Clinically relevant psychological alteration 2 week precede enrollment interfere , researcher opinion , goal study Patients treat Ciclosporin A Subjects remove trial shall replace .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Invasive fungal infection</keyword>
	<keyword>Liver Transplantation</keyword>
	<keyword>Organ Transplantation</keyword>
	<keyword>Mycoses</keyword>
	<keyword>Fungus Diseases</keyword>
	<keyword>Antifungal Agents</keyword>
	<keyword>Invasive Mycosis</keyword>
</DOC>